Global Antihistamine Drugs Market is Anticipated to Witness High Growth Owing to Increasing Prevalence of Allergic Diseases
Global Antihistamine Drugs Market is Anticipated to Witness High Growth Owing to Increasing Prevalence of Allergic Diseases
Antihistamine drugs are medications that block the effects of histamine in the body by competing against histamine for binding sites on tissues and cells.

Antihistamine drugs are medications that block the effects of histamine in the body by competing against histamine for binding sites on tissues and cells. They are commonly used for treating allergic reactions and symptoms related to allergic conditions. The growing prevalence of allergic rhinitis, also known as hay fever, affecting globally over 500 million people every year is resulting in an increased demand for antihistamine medications like oral and topical antihistamines.

The Global Antihistamine Drugs Market is estimated to be valued at US$ 78.89 BN in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Antihistamine Drugs are Bayer AG, Almirall S.A, GlaxoSmithKline, Johnson and Johnson, Sanofi, Pfizer Inc., Sun Pharmaceutical Industries Limited, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Viatris Inc., Arlak Biotech, Aden Healthcare, Sandoz Group AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, and Cipla. These players are actively focusing on strengthening their distribution channels and enhancing access to antihistamines across markets globally.

The increasing cases of seasonal allergies and growing awareness regarding the importance of early treatment for allergic symptoms present significant growth opportunities for players in the Global Antihistamine Drugs Market Demand . Moreover, manufacturing of antihistamine drugs with reduced side effects is also supporting the adoption across various age groups.

The major pharmaceutical players are expanding their global footprint by strengthening presence in high potential markets including Asia Pacific, Latin America, and Africa through acquisitions and partnerships with regional pharmaceutical distributors. This helps cater to the increasing demand for antihistamines in emerging countries.

Market drivers: The increasing prevalence of allergic diseases such as allergic rhinitis, asthma, and anaphylaxis owing to changes in environment, diet, and lifestyle habits is a major market driver. Easy availability of generic over-the-counter antihistamines with reduced prescription requirements is also fueling the market growth.

Market restraints: Side effects associated with intake of antihistamines like drowsiness, blurred vision, dry mouth, and constipation limit their adoption. Strong competition from substitute drugs and natural remedies for allergies also presents a challenge for major players. In addition, availability of low-cost generics further restrains the pricing flexibility of established brands.


Segment Analysis
The global antihistamine drugs market can be segmented into H1-Antihistamines and H2-Antihistamines. The H1-Antihistamines segment currently dominates the global antihistamine drugs market with over 60% share. These drugs are highly prescribed for treating allergies like allergic rhinitis, urticaria and other conditions. The H1-Antihistamines sub segment is further divided in first generation, second generation and third generation H1-Antihistamines. Among them, the first generation H1-Antihistamines command the largest share in this sub segment due to affordable pricing of generic drugs and extensive availability. However, the second generation H1-Antihistamines are growing at a higher rate owing to their improved safety profile over the first generation and strong presence of patent protected branded drugs in this category.

Global Analysis
In terms of regions, North America dominates the global antihistamine drugs market due to strong healthcare infrastructure, rising allergy and high uptake of novel branded drugs in the region. Europe is the second leading regional market driven by increasing healthcare spending, numerous government initiatives and growth of biologics production facilities. Asia Pacific is recognized as the fastest growing regional market with a CAGR of over 10% during the forecast period. Factors such as increasing patient awareness, improving healthcare infrastructure and rising research funding is fueling the growth of antihistamine drugs market in Asia Pacific region. Emerging countries like China, India and South Korea are expected to offer lucrative opportunities for market players in Asia Pacific.

Get more insights, On Global Antihistamine Drugs Market

Check more trending articles related to this topic: Diagnostic Radioisotopes Market

disclaimer

What's your reaction?

Comments

https://www.timessquarereporter.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!

Facebook Conversations